KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Inventory (2017 - 2025)

Historic Inventory for Ionis Pharmaceuticals (IONS) over the last 9 years, with Q3 2025 value amounting to $10.5 million.

  • Ionis Pharmaceuticals' Inventory fell 6320.12% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 6320.12%. This contributed to the annual value of $12.5 million for FY2024, which is 6814.94% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Inventory stood at $10.5 million for Q3 2025, which was down 6320.12% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Inventory ranged from a high of $30.3 million in Q1 2024 and a low of $7.4 million during Q4 2023
  • For the 5-year period, Ionis Pharmaceuticals' Inventory averaged around $20.6 million, with its median value being $22.2 million (2023).
  • Its Inventory has fluctuated over the past 5 years, first soared by 6814.94% in 2024, then tumbled by 7047.31% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Inventory (Quarter) stood at $24.8 million in 2021, then dropped by 11.18% to $22.0 million in 2022, then plummeted by 66.23% to $7.4 million in 2023, then soared by 68.15% to $12.5 million in 2024, then dropped by 16.32% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q3 2025, $8.5 million for Q2 2025, and $11.5 million during Q1 2025.